The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
Open accessAbstract
Purpose: The first planned interim analysis (median follow-up, 3 years) of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine derivative S-1 significantly improved overall survival, the primary end point. The results were therefore opened at the recommendation of an independent data and safety monitoring committee. We report 5-year follow-up data on patients enrolled onto the ACTS-GC study. Patients and Methods: Patients with histologically confirmed stage II or III gastric cancer who underwent gastrectomy with D2 lymphadenectomy were randomly assigned to receive S-1 after surgery or surgery only. S-1 (80 to 120 mg per day) was given for 4 weeks, followed by 2 weeks of rest. This 6-week cycle was repeated for 1 year. The primary end point was overall survival, and the secondary end points were relapse-free survival and safety. Results: The overall survival rate at 5 years was 71.7% in the S-1 group and 61.1% in the surgery-only group (hazard ratio [HR], 0.669; 95% CI, 0.540 to 0.828). The relapse-free survival rate at 5 years was 65.4% in the S-1 group and 53.1% in the surgery-only group (HR, 0.653; 95% CI, 0.537 to 0.793). Subgroup analyses according to principal demographic factors such as sex, age, disease stage, and histologic type showed no interaction between treatment and any characteristic. Conclusion: On the basis of 5-year follow-up data, postoperative adjuvant therapy with S-1 was confirmed to improve overall survival and relapse-free survival in patients with stage II or III gastric cancer who had undergone D2 gastrectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072252 · Cited by 2,517
Self-citationJapanese Classification of Gastric Carcinoma – 2nd English Edition –
Japanese Gastric Cancer Association (1998) · Gastric Cancer · doi:10.1007/pl00011681 · Cited by 2,170
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Songun, I., Putter, H., Kranenbarg, E. M.-K., Sasako, M., & van de Velde, C. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70070-x · Cited by 1,765
Self-citationExtended Lymph-Node Dissection for Gastric Cancer
Bonenkamp, J. J., Hermans, J., Sasako, M., Welvaart, K., Songun, I., Meyer, S., Plukker, J. T. M., Van Elk, P., Obertop, H., Gouma, D. J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401202 · Cited by 1,583
Self-citationGastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Okines, A., Verheij, M., Allum, W., Cunningham, D., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq164 · Cited by 1,300
Bonenkamp, J. J., Songun, I., Welvaart, K., van de Velde, C. J. H., Hermans, J., Sasako, M., Plukker, J. T. M., van Elk, P., Obertop, H., Gouma, D. J., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90637-1 · Cited by 1,026
Self-citationShirasaka, T., Shimamato, Y., Ohshimo, H., Yamaguchi, M., Kato, T., Yonekura, K., & Fukushima, M. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199607000-00010 · Cited by 820
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis
(2010) · JAMA · doi:10.1001/jama.2010.534 · Cited by 794
Sakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., Mitachi, Y., & Taguchi, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00211-1 · Cited by 565
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
Koizumi, W., Kurihara, M., Nakano, S., & Hasegawa, K. (2000) · Oncology · doi:10.1159/000012099 · Cited by 440
Earle, C. C., & Maroun, J. A. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00076-3 · Cited by 411
Acdonald, J. O. S. M., Malley, R., Acqueline, J., Undahl, S. C. A. H., Orman, N., Stes, C. E., Temmermann, G. R. N. S., Aller, D. A. G. H., Affer, J., Jani, A., et al. (2012) · Cited by 402
Ajani, J. A., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3956 · Cited by 182
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio, R. B. (1999) · PubMed · Cited by 67
Cited by
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Japanese Gastric Cancer Association (2017) · Gastric Cancer · doi:10.1007/s10120-016-0622-4 · Cited by 2,429
Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30354-3 · Cited by 1,793
Japanese gastric cancer treatment guidelines 2018 (5th edition)
Japanese Gastric Cancer Association (2021) · Gastric Cancer · doi:10.1007/s10120-020-01042-y · Cited by 1,749
Bang, Y.-J., Kim, Y.-W., Yang, H.-K., Chung, H. C., Park, Y.-K., Lee, K. H., Lee, K.-W., Kim, Y. H., Noh, S.-I., Cho, J. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,705
Current treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
Metadata
- Authors
- Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., Nakajima, T., & Ohashi, Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-11-20
- Volume
- 29
- Issue
- 33
- Pages
- 4387-4393
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2098719201
- Cited by
- 1,434
- References
- 20
- FWCI
- 51.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.